Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 347

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS)

Open access
Siddiqui, Sana, Mateen, Somaiya, Ahmad, Rizwan, Moin, Shagufta·2022·Journal of Assisted Reproduction and Genetics
DOI 10.1007/s10815-022-02625-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10815-022-02625-7

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 241

  1. A. Szilagyi and I. Szabo, “Endocrine characteristics of polycystic ovary syndrome (PCOS),” IJEB Vol.41(07) [July 2003], 2003, Accessed: Jan. 18, 2022. [Online]. Available: http://nopr.niscair.res.in/handle/123456789/17119
  2. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Rev Endocrinol. 2018;14(5):270–84. · DOI · Paper page
  3. R. Azziz et al., “Polycystic ovary syndrome,” Nature Reviews Disease Primers 2016 2:1 https://doi.org/10.1038/nrdp.2016.57. · DOI · Paper page
  4. Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–73. https://doi.org/10.1210/JS.2019-00078. · DOI · Paper page
  5. Mehreen TS, Ranjani H, Kamalesh R, Ram U, Anjana RM, Mohan V. Prevalence of polycystic ovarian syndrome among adolescents and young women in India. J Diabetol. 2022;12(3):319. https://doi.org/10.4103/JOD.JOD_105_20. · DOI
  6. M. F. Yii, C. E. D. Lim, X. Luo, W. S. F. Wong, N. C. L. Cheng, and X. Zhan, “Polycystic ovarian syndrome in adolescence,” https://doi.org/10.1080/09513590903015551 2009 25 10:634–639 https://doi.org/10.1080/09513590903015551. · DOI
  7. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R, Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol. 2011;24(1):15–20. https://doi.org/10.1016/J.JPAG.2010.06.003. · DOI
  8. S. Balaji et al., “Urban rural comparisons of polycystic ovary syndrome burden among adolescent girls in a hospital setting in India,” BioMed Research International 2015 https://doi.org/10.1155/2015/158951 · DOI
  9. Dumesic DA, Meldrum DR, Katz-Jaffe MG, Krisher RL, Schoolcraft WB. Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. Fertil Steril. 2015;103(2):303–16. https://doi.org/10.1016/J.FERTNSTERT.2014.11.015. · DOI · Paper page
  10. Liu Y, et al. Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality. J Assist Reprod Genet. 2021;38(2):471–7. https://doi.org/10.1007/S10815-020-02014-Y/TABLES/5. · DOI
  11. Y. Dincer, T. Akcay, T. Erdem, E. Ilker Saygili, and S. Gundogdu, “DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome,” 65 8:721–728 2009 https://doi.org/10.1080/00365510500375263 · DOI
  12. K. Polak, A. Czyzyk, T. Simoncini, and B. Meczekalski, “New markers of insulin resistance in polycystic ovary syndrome,” J Endocrinol Investi 2016 https://doi.org/10.1007/S40618-016-0523-8 · DOI · Paper page
  13. Manco M, et al. Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index. PLoS ONE. 2014;9(4):e92995. https://doi.org/10.1371/JOURNAL.PONE.0092995. · DOI
  14. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16(6):1255–60. https://doi.org/10.1093/HUMREP/16.6.1255. · DOI
  15. Murri M, Luque-ramírez M, Insenser M, Ojeda-ojeda M, Escobar-morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013;19(3):268–88. https://doi.org/10.1093/HUMUPD/DMS059. · DOI · Paper page
  16. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20(2):193–205. https://doi.org/10.1016/J.BEEM.2006.02.005. · DOI
  17. B. C. J. M. Fauser et al., “Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,” Fertil Steril,97 1 2012, https://doi.org/10.1016/J.FERTNSTERT.2011.09.024. · DOI · Paper page
  18. Azziz R, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88. https://doi.org/10.1016/J.FERTNSTERT.2008.06.035. · DOI · Paper page
  19. R. Legro, S. Arslanian, … D. E.-T. J. of, and undefined 2013, “Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline,” academic.oup.com, Accessed: Aug. 20, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/98/12/4565/2833703 · DOI · Paper page
  20. “National Institute of Health (NIH)-Evidence based... - Google Scholar.” https://scholar.google.co.in/scholar?hl=en&as_sdt=0%2C5&q=National+Institute+of+Health+%28NIH%29-Evidence+based+workshop+on+Polycystic+Ovary+Syndrome+%282012%29&btnG= (accessed Aug. 20, 2022).
  21. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53–8. https://doi.org/10.1016/S0015-0282(00)01662-9. · DOI · Paper page
  22. R. S. Legro, D. Driscoll, J. F. Strauss, J. Fox, and A. Dunaif, “Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome,” Proceedings of the National Academy of Sciences, 95, 25, 1998. · DOI · Paper page
  23. Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: a review article. Eur J Obstet Gynecol Reproduct Biol. 2019;3:100060. https://doi.org/10.1016/J.EUROX.2019.100060. · DOI · Paper page
  24. de Andrade VHL, et al. Current aspects of polycystic ovary syndrome: a literature review. Rev Assoc Med Bras. 2016;62(9):867–71. https://doi.org/10.1590/1806-9282.62.09.867. · DOI
  25. da Silva BB, et al. Morphological and morphometric analysis of the adrenal cortex of androgenized female rats. Gynecol Obstet Invest. 2007;64(1):44–8. https://doi.org/10.1159/000098956. · DOI
  26. A. Dunaif and C. B. Book, “Insulin resistance in the polycystic ovary syndrome,” Clinical Research in Diabetes and Obesity, 249–274, 1997, https://doi.org/10.1007/978-1-4757-3906-0_14. · DOI
  27. R. Dumitrescu, C. Mehedintu, I. Briceag, V. L. Purcarea, and D. Hudita, “The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms,” Journal of Medicine and Life, vol. 8, no. 2, p. 142, Apr. 2015, Accessed: Jan. 20, 2022. [Online]. Available: /pmc/articles/PMC4392092/
  28. Chun S. Relationship between early follicular serum estrone level and other hormonal or ultrasonographic parameters in women with polycystic ovary syndrome. Gynecol Endocrinol. 2020;36(2):143–7. https://doi.org/10.1080/09513590.2019.1633296. · DOI
  29. DeVane GW, Czekala NM, Judd HL, Yen SSC. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol. 1975;121(4):496–500. https://doi.org/10.1016/0002-9378(75)90081-2. · DOI · Paper page
  30. E. Doh et al., “The relationship between adiposity and insulin sensitivity in african women living with the polycystic ovarian syndrome: a clamp study,” International Journal of Endocrinology, vol. 2016, https://doi.org/10.1155/2016/9201701. · DOI
  31. R. Pasquali and A. Gambineri, “New perspectives on the definition and management of polycystic ovary syndrome,” Journal of Endocrinological Investigation 2018 41:10, vol. 41 10:1123–1135, 2018, https://doi.org/10.1007/S40618-018-0832-1. · DOI
  32. Moll GW, Rosenfield RL. Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. J Pediatr. 1983;102(3):461–4. https://doi.org/10.1016/S0022-3476(83)80678-7. · DOI
  33. van Hooff MHA, Voorhorst FJ, Kaptein MBH, Hirasing RA, Koppenaal C, Schoemaker J. Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril. 2000;74(1):49–58. https://doi.org/10.1016/S0015-0282(00)00584-7. · DOI
  34. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520. https://doi.org/10.1210/ER.2015-1104. · DOI · Paper page
  35. Bulsara J, Patel P, Soni A, Acharya S. A review: brief insight into polycystic ovarian syndrome. Endocr Metab Sci. 2021;3:100085. https://doi.org/10.1016/J.ENDMTS.2021.100085. · DOI
  36. D. E. Moller and J. S. Flier, “Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, Acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance),” 319, 23:1526–1529 2010, https://doi.org/10.1056/NEJM198812083192306. · DOI
  37. Aversa A, et al. Fundamental concepts and novel aspects of polycystic ovarian syndrome: expert consensus resolutions. Front Endocrinol. 2020;11:516. https://doi.org/10.3389/FENDO.2020.00516. · DOI
  38. Caprio S. Insulin: the other anabolic hormone of puberty. Acta Pædiatrica. 1999;88(433):84–7. https://doi.org/10.1111/J.1651-2227.1999.TB14410.X. · DOI · Paper page
  39. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab. 2006;8(2):136–45. https://doi.org/10.1111/J.1463-1326.2005.00496.X. · DOI
  40. Seow KM, Juan CC, Hsu YP, Hwang JL, Huang LW, Ho LT. Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery. Hum Reprod. 2007;22(4):1003–10. https://doi.org/10.1093/HUMREP/DEL466. · DOI
  41. Corbould A, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab. 2005;288(5):51–5. https://doi.org/10.1152/AJPENDO.00361.2004/ASSET/IMAGES/LARGE/ZH10050520890006.JPEG. · DOI
  42. Chen L, Xu WM, Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. Fertil Steril. 2014;102(4):1167-1174.e4. https://doi.org/10.1016/J.FERTNSTERT.2014.06.027. · DOI
  43. J. L. Evans, B. A. Maddux, and I. D. Goldfine, “The molecular basis for oxidative stress-induced insulin resistance,” https://home.liebertpub.com/ars, 7, 7–8:1040–1052, 2005, https://doi.org/10.1089/ARS.2005.7.1040. · DOI · Paper page
  44. González F, Rote NS, Minium J, Kirwan JP. reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):336–40. https://doi.org/10.1210/JC.2005-1696. · DOI · Paper page
  45. V. M. Victor, M. Rocha, E. Sola, C. Banuls, K. Garcia-Malpartida, and A. Hernandez- Mijares, “Oxidative stress, endothelial dysfunction and atherosclerosis,” Current Pharmaceutical Design, 15, 26:2988–3002, 2009, https://doi.org/10.2174/138161209789058093 · DOI · Paper page
  46. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease☆. Clin Biochem. 2001;34(5):407–13. https://doi.org/10.1016/S0009-9120(01)00245-4. · DOI
  47. Ziech D, Franco R, Pappa A, Panayiotidis MI. Reactive oxygen species (ROS)––induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res/Fundam Mol Mechan Mutagen. 2011;711(1–2):167–73. https://doi.org/10.1016/J.MRFMMM.2011.02.015. · DOI
  48. Donkena KV, Young CYF, Tindall DJ. oxidative stress and dna methylation in prostate cancer. Obstet Gynecol Int. 2010;2010:1–14. https://doi.org/10.1155/2010/302051. · DOI
  49. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008;266(1):6–11. https://doi.org/10.1016/J.CANLET.2008.02.026. · DOI · Paper page
  50. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51. https://doi.org/10.1093/HUMREP/DEP399. · DOI · Paper page
  51. T. Zuo, M. Zhu, and W. Xu, “Roles of oxidative stress in polycystic ovary syndrome and cancers,” Oxidative Medicine and Cellular Longevity, vol. 2016, 2016, https://doi.org/10.1155/2016/8589318. · DOI · Paper page
  52. Ozata M, et al. Increased oxidative stress and hypozincemia in male obesity. Clin Biochem. 2002;35(8):627–31. https://doi.org/10.1016/S0009-9120(02)00363-6. · DOI
  53. Couillard C, et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005;90(12):6454–9. https://doi.org/10.1210/JC.2004-2438. · DOI
  54. Hu Y, Zhao Y, Ren D, Guo J, Luo Y, Yang X. Hypoglycemic and hepatoprotective effects of d - chiro -inositol-enriched tartary buckwheat extract in high fructose-fed mice. Food Funct. 2015;6(12):3760–9. https://doi.org/10.1039/C5FO00612K. · DOI
  55. Castro MC, Massa ML, Arbeláez LG, Schinella G, Gagliardino JJ, Francini F. Fructose-induced inflammation, insulin resistance and oxidative stress: a liver pathological triad effectively disrupted by lipoic acid. Life Sci. 2015;137:1–6. https://doi.org/10.1016/J.LFS.2015.07.010. · DOI
  56. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30–41. https://doi.org/10.1016/J.MCE.2010.08.002. · DOI
  57. Yilmaz M, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333–40. https://doi.org/10.1093/HUMREP/DEI258. · DOI · Paper page
  58. Piotrowski PC, et al. Antioxidants inhibit expression of genes involved in testosterone production by theca-interstitial cells. Fertil Steril. 2005;84:S7. https://doi.org/10.1016/J.FERTNSTERT.2005.07.016. · DOI
  59. Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des. 2012;18(3):270–82. https://doi.org/10.2174/138161212799040457. · DOI
  60. Piperi C, Adamopoulos C, Dalagiorgou G, Diamanti-Kandarakis E, Papavassiliou AG. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic Diseases. J Clin Endocrinol Metab. 2012;97(7):2231–42. https://doi.org/10.1210/JC.2011-3408. · DOI
  61. Garg D, Merhi Z. Advanced glycation end products: link between diet and ovulatory dysfunction in PCOS? Nutrients. 2015;7(12):10129–44. https://doi.org/10.3390/NU7125524. · DOI
  62. Diamanti-Kandarakis E, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007;127:581–9. https://doi.org/10.1007/s00418-006-0265-3. · DOI
  63. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9–21. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2007.07.025. · DOI
  64. Tantalaki E, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones. 2014;13(1):65–73. https://doi.org/10.1007/BF03401321. · DOI
  65. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2005;62(1):37–43. https://doi.org/10.1111/J.1365-2265.2004.02170.X. · DOI
  66. Uribarri J, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol Series A. 2007;62(4):427–33. https://doi.org/10.1093/GERONA/62.4.427. · DOI · Paper page
  67. Cai W, di Gao Q, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8(7):337–46. https://doi.org/10.1007/BF03402014/FIGURES/5. · DOI
  68. Tatone C, Eichenlaub-Ritter U, Amicarelli F. Dicarbonyl stress and glyoxalases in ovarian function. Biochem Soc Trans. 2014;42(2):433–8. https://doi.org/10.1042/BST20140023. · DOI
  69. Unoki H, Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des. 2008;14(10):987–9. https://doi.org/10.2174/138161208784139747. · DOI
  70. Merhi Z. Advanced glycation end products and their relevance in female reproduction. Hum Reprod. 2014;29(1):135–45. https://doi.org/10.1093/HUMREP/DET383. · DOI
  71. Koyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(12):2587–93. https://doi.org/10.1161/01.ATV.0000190660.32863.cd. · DOI · Paper page
  72. P. Pigny, S. Jonard, … Y. R.-T. J. of C., and undefined 2006, “Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome,” academic.oup.com, Accessed: Aug. 20, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/91/3/941/2843410 · DOI
  73. C. Cook, Y. Siow, A. Brenner, M. F.-F. and sterility, and undefined 2002, “Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal,” Elsevier, Accessed: Aug. 20, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028201029442?casa_token=3ObG0fuGhhUAAAAA:ffl0nsmfH5O14HW73cx-pjnR6AKND3wtBrE_Fem1J7RWz111t5uJqetqOOB7b23MjfNEsY7PeQ38
  74. L. Pellatt, L. Hanna, M. Brincat, … R. G.-T. J. of, and undefined 2007, “Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries,” academic.oup.com, Accessed: Aug. 20, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/92/1/240/2598594 · DOI · Paper page
  75. Tata B, et al. Elevated prenatal anti-Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24(6):834–7. https://doi.org/10.1038/S41591-018-0035-5. · DOI · Paper page
  76. N. Mimouni, I. Paiva, A. Barbotin, F. T.-C. metabolism, and undefined 2021, “Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1550413121000048
  77. R. Tal, D. Seifer, M. Khanimov, … H. M.-A. journal of, and undefined 2014, “Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0002937814001689
  78. R. Homburg, A. Ray, P. Bhide, A. Gudi, A. S.-… Reproduction, and undefined 2013, “The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/humrep/article-abstract/28/4/1077/653152 · DOI
  79. Y. Lin et al., “Antimüllerian hormone and polycystic ovary syndrome,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028211005863?casa_token=qb4h0HFI1noAAAAA:Od82bVmuVqtLcNfJlQkGjcPuNVgY-Ptj2N6QM2VcyynJt-TcHxkjQgRMD9TB68hJClVDQTr82HY
  80. A. Piouka, D. Farmakiotis, I. Katsikis, D. Macut, S. Gerou, and D. Panidis, “Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: Relationship with increased luteinizing hormone levels,” American Journal of Physiology - Endocrinology and Metabolism, 296, 2, 2009, https://doi.org/10.1152/AJPENDO.90684.2008. · DOI
  81. Eldar-Geva T, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005;20(7):1814–9. https://doi.org/10.1093/HUMREP/DEH873. · DOI
  82. “Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/88/12/5957/2661509 · DOI · Paper page
  83. Hines M, Golombok S, Rust J, Johnston KJ, Golding J. Testosterone during pregnancy and gender role behavior of preschool children: a longitudinal, population study. Child Dev. 2002;73(6):1678–87. https://doi.org/10.1111/1467-8624.00498. · DOI
  84. R. Hart, D. Sloboda, D. Doherty, R. N.-F. and sterility, and undefined 2010, “Circulating maternal testosterone concentrations at 18 weeks of gestation predict circulating levels of antimüllerian hormone in adolescence: a prospective,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028209043192?casa_token=w61Hv4KIJ3gAAAAA:BrYdCIuHRtNjgg607BUfC_sKuz4L0X7fqWWYQTAKc6h4Yn29mwqO4BQFvA5v-RiyKTtgzQ9TI9Y
  85. Webber LJ, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–21. https://doi.org/10.1016/S0140-6736(03)14410-8. · DOI · Paper page
  86. M. Maliqueo, H. E. Lara, F. Sá nchez, B. rbara Echiburú, N. Crisosto, and T. Sir-Petermann, “Placental steroidogenesis in pregnant women with polycystic ovary syndrome,” Elsevier, 2013, https://doi.org/10.1016/j.ejogrb.2012.10.015. · DOI
  87. E. Kandaraki, … A. C.-T. J. of, and undefined 2011, “Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/96/3/E480/2597282 · DOI · Paper page
  88. L. Akin et al., “The endocrine disruptor bisphenol A may play a role in the aetiopathogenesis of polycystic ovary syndrome in adolescent girls.,” Acta Paediatrica (Oslo, Norway : 1992), 104, 4:e171–7, 2015, https://doi.org/10.1111/APA.12885 · DOI
  89. A. Rutkowska, E. D.-K.-F. and sterility, and undefined 2016, “Polycystic ovary syndrome and environmental toxins,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028216627280
  90. D. Micic, V. Popovic, M. Nesovic, … M. S.-J. of steroid, and undefined 1988, “Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/0022473188903445
  91. A. Dumont, G. Robin, D. D. Endocrinology, D. and, and undefined 2018, “Anti-müllerian hormone in the pathophysiology and diagnosis of polycystic ovarian syndrome,” journals.lww.com, 2018, https://doi.org/10.1097/MED.0000000000000445 · DOI
  92. S. Franks, C. Gilling-Smith, N. Gharani, and M. McCarthy, “Pathogenesis of polycystic ovary syndrome: evidence for a genetically determined disorder of ovarian androgen production,”, 3, 2:77–79, 2009, https://doi.org/10.1080/1464727002000198731 · DOI
  93. Gharani N, et al. Association of the steroid synthesis gene Cyp11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 1997;6(3):397–402. https://doi.org/10.1093/HMG/6.3.397. · DOI · Paper page
  94. Reddy KR, et al. CYP11A1 microsatellite (tttta)n polymorphism in PCOS women from South India. J Assist Reprod Genet. 2014;31(7):857–63. https://doi.org/10.1007/S10815-014-0236-X/TABLES/3. · DOI
  95. Zhang CW, et al. Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women. Mol Biol Rep. 2012;39(8):8379–85. https://doi.org/10.1007/S11033-012-1688-7/TABLES/7. · DOI
  96. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome. Fertil Steril. 1990;53(5):785–91. https://doi.org/10.1016/S0015-0282(16)53510-9. · DOI
  97. Rosenfield RL, Barnes RB, Ehrmann DA. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994;79(6):1686–92. https://doi.org/10.1210/JCEM.79.6.7989476. · DOI
  98. Carey AH, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3(10):1873–6. https://doi.org/10.1093/HMG/3.10.1873. · DOI
  99. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci. 1995;92(23):10619–23. https://doi.org/10.1073/PNAS.92.23.10619. · DOI · Paper page
  100. D. W. Nebert et al., “The P450 gene superfamily: recommended nomenclature,” http://www.liebertpub.com/dna, 6, 1:1–11, 2009, https://doi.org/10.1089/DNA.1987.6.1. · DOI · Paper page
  101. S. Chen et al., “Human Aromatase: cDNA cloning, southern blot analysis, and assignment of the gene to chromosome 15,” http://www.liebertpub.com/dna, 7, 1:27–38, 2009, https://doi.org/10.1089/DNA.1988.7.27. · DOI
  102. Harada N, et al. Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem. 1992;267(7):4781–5. https://doi.org/10.1016/S0021-9258(18)42900-6. · DOI
  103. Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod. 1998;4(1):1–8. https://doi.org/10.1093/MOLEHR/4.1.1. · DOI
  104. J. L. Jin et al., “Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women.,” BMC Med Genet, 10, 1:139, 2009, https://doi.org/10.1186/1471-2350-10-139/TABLES/3. · DOI
  105. Escobar-Morreale H, Pazos F, Potau N, Garcia-Robles R, Sancho JM, Varela C. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17α. Fertil Steril. 1994;62(3):521–30. https://doi.org/10.1016/S0015-0282(16)56940-4. · DOI
  106. Azziz R, Bradley EL, Potter HD, Boots LR. Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab. 1995;80(2):400–5. https://doi.org/10.1210/JCEM.80.2.7852496. · DOI
  107. Witchel SF, Kahsar-Miller M, Aston CE, White C, Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertil Steril. 2005;83(2):371–5. https://doi.org/10.1016/J.FERTNSTERT.2004.10.027. · DOI
  108. D. B. Lubahn, D. R. Joseph, P. M. Sullivan, H. F. Willard, F. S. French, and E. M. Wilson, “Cloning of human androgen receptor complementary dna and localization to the X chromosome,” Science (1979), 240, 4850:327–330, 1988, https://doi.org/10.1126/SCIENCE.3353727. · DOI · Paper page
  109. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene cag trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab. 2000;85(9):3484–8. https://doi.org/10.1210/JCEM.85.9.6832. · DOI
  110. Edmunds SEJ, Stubbs AP, Santos AA, Wilkinson ML. Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line. J Steroid Biochem Mol Biol. 1990;37(5):733–9. https://doi.org/10.1016/0960-0760(90)90358-R. · DOI
  111. Selby C. Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990;27(6):532–41. https://doi.org/10.1177/000456329002700603. · DOI
  112. Bérubé D, Séralini GE, Gagné R, Hammond GL. Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17p12→p13). Cytogenet Genome Res. 1990;54(1–2):65–7. https://doi.org/10.1159/000132958. · DOI
  113. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab. 2003;88(12):5976–80. https://doi.org/10.1210/JC.2003-030197. · DOI
  114. Wickham EP, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(4):E719–27. https://doi.org/10.1210/JC.2010-1842. · DOI
  115. C. Chen, J. Smothers, A. Lange, J. E. Nestler, J. F. Strauss, and E. P. Wickham, “Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome,” Minerva Endocrinol, vol. 35, no. 4, p. 271, Dec. 2010, Accessed: Jan. 24, 2022. [Online]. Available: /pmc/articles/PMC3683392/
  116. Furui K, et al. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab. 1994;78(1):107–13. https://doi.org/10.1210/JCEM.78.1.7904610. · DOI
  117. Okuda K, Yamada T, Imoto H, Komatsubara H, Sugimoto O. Antigenic Alteration of an Anomalous Human Luteinizing Hormone Caused by Two Chorionic Gonadotropin-Type Amino-Acid Substitutions. Biochem Biophys Res Commun. 1994;200(1):584–90. https://doi.org/10.1006/BBRC.1994.1488. · DOI
  118. Haavisto AM, Pettersson K, Bergendahl M, Virkamäki A, Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 1995;80(4):1257–63. https://doi.org/10.1210/JCEM.80.4.7714098. · DOI
  119. Roy AC, Liao WX, Chen Y, Arulkumaran S, Ratnam SS. Identification of seven novel mutations in LH β-subunit gene by SSCP. Mol Cellular Biochem. 1996;165(2):151–3. https://doi.org/10.1007/BF00229477. · DOI
  120. Takahashi K, et al. Influence of missense mutation and silent mutation of LHβ-subunit gene in Japanese patients with ovulatory disorders. Eur J Human Genet. 2003;11(5):402–8. https://doi.org/10.1038/sj.ejhg.5200968. · DOI
  121. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update. 2001;7(4):405–10. https://doi.org/10.1093/HUMUPD/7.4.405. · DOI
  122. A. Al-Hayawi, “The FSHR polymorphisms association with polycystic ovary syndrome in women of Erbil, Kurdistan in North of Iraq”, https://doi.org/10.30526/2017.IHSCICONF.1799. · DOI
  123. Gorsic LK, et al. Pathogenic Anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(8):2862–72. https://doi.org/10.1210/JC.2017-00612. · DOI
  124. Knight PG, Glister C. Potential local regulatory functions of inhibins, activins and follistatin in the ovary. Reprod. 2001;121(4):503–12. https://doi.org/10.1530/REP.0.1210503. · DOI · Paper page
  125. Guo Q, Kumar TR, Woodruff T, Hadsell LA, Demayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol. 1998;12(1):96–106. https://doi.org/10.1210/MEND.12.1.0053. · DOI
  126. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165–74. https://doi.org/10.2337/DIAB.38.9.1165. · DOI · Paper page
  127. Munir I, et al. Insulin augmentation of 17α-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinol. 2004;145(1):175–83. https://doi.org/10.1210/EN.2003-0329. · DOI
  128. N. Cataldo, L. Giudice, L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice, “The insulin-related ovarian regulatory system in health and disease,” 1999, https://doi.org/10.1210/edrv.20.4.0374. · DOI · Paper page
  129. Junien C, van Heyningen V. Report of the committee on the genetic constitution of chromosome 11. Cytogenet Genome Res. 1990;55(1–4):153–69. https://doi.org/10.1159/000133007. · DOI
  130. Bell GI, Selby MJ, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature. 1982;295(5844):31–5. https://doi.org/10.1038/295031a0. · DOI
  131. Waterworth DM, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet. 1997;349(9057):986–90. https://doi.org/10.1016/S0140-6736(96)08368-7. · DOI · Paper page
  132. Goldfine ID. The insulin receptor: molecular biology and transmembrane signaling. Endocr Rev. 1987;8(3):235–55. https://doi.org/10.1210/EDRV-8-3-235. · DOI
  133. Sorbara LR, et al. Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism. 1994;43(12):1568–74. https://doi.org/10.1016/0026-0495(94)90018-3. · DOI
  134. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O’Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1996;81(5):1979–83. https://doi.org/10.1210/JCEM.81.5.8626868. · DOI
  135. Tucci S, et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab. 2001;86(1):446–9. https://doi.org/10.1210/JCEM.86.1.7274. · DOI
  136. Urbanek M, et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab. 2005;90(12):6623–9. https://doi.org/10.1210/JC.2005-0622. · DOI
  137. Siegel S, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril. 2002;78(6):1240–3. https://doi.org/10.1016/S0015-0282(02)04241-3. · DOI
  138. White MF. IRS proteins and the common path to diabetes. Am J Physiol - Endocrinol Metab. 2002;283(3):46–53. https://doi.org/10.1152/AJPENDO.00514.2001/ASSET/IMAGES/LARGE/H10920962005.JPEG. · DOI
  139. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril. 2005;84(2):407–12. https://doi.org/10.1016/J.FERTNSTERT.2005.01.133. · DOI
  140. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15(12):2099–111. https://doi.org/10.1096/FJ.01-0009REV. · DOI · Paper page
  141. Paz K, et al. A molecular basis for insulin resistance. J Biol Chem. 1997;272(47):29911–8. https://doi.org/10.1074/jbc.272.47.29911. · DOI · Paper page
  142. P. Gual, T. Gonzalez, T. Grémeaux, … R. B.-J. of B., and undefined 2003, “Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes,” ASBMB, Accessed: Aug. 21, 2022. [Online]. Available: https://www.jbc.org/article/S0021-9258(20)84607-9/abstract · DOI
  143. Potashnik R, Bloch-Damti A, Bashan N, Rudich A. IRS1 degradation and increased serine phosphorylation cannot predict the degree of metabolic insulin resistance induced by oxidative stress. Diabetologia. 2003;46(5):639–48. https://doi.org/10.1007/S00125-003-1097-5/FIGURES/7. · DOI
  144. A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif, “Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome,” Diabetes, vol. 55, no. 3, pp. 751–760, Mar. 2006, Accessed: Aug. 21, 2022. [Online]. Available: https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=00121797&v=2.1&it=r&id=GALE%7CA143248675&sid=googleScholar&linkaccess=fulltext · DOI
  145. R. Dumitrescu, “Metformin-clinical pharmacology in PCOs,” Journal of Medicine and Life, vol. 8, pp. 187–192.
  146. Dunaif A. Drug Insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4(5):272–83. https://doi.org/10.1038/NCPENDMET0787. · DOI
  147. K. Blomquist, V. Milsom, R. Barnes, … A. B.-C., and undefined 2012, “Metabolic syndrome in obese men and women with binge eating disorder: developmental trajectories of eating and weight-related behaviors,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0010440X12000272
  148. T Tang RJ Norman AH Balen JM Lord 2003 Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome Cochrane Database Syst Revhttps://doi.org/10.1002/14651858.CD003053 · DOI · Paper page
  149. G. Attia, W. Rainey, B. C.-F. and sterility, and undefined 2001, “Metformin directly inhibits androgen production in human thecal cells,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028201019756?casa_token=kndwMryayKIAAAAA:lZrv1YXr-yJzXhJGMshXQx12j6blX0mdSjJF0myv0603DHP9XWYFSxcvTR6wUXeQO7XOJMdcya8
  150. S. Thatcher, E. J.-F. and sterility, and undefined 2006, “Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin,” Elsevier, Accessed: Aug. 21, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0015028205042123?casa_token=OpclRqBuXV8AAAAA:LPjTc3bOEsCb5N0B0mrzb47b8dIUCV4uwhK3RpnFozx9JWfhzRv8iBCTXr6VMFbkWxIIPpGE9qM
  151. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858–64. https://doi.org/10.1093/HUMREP/17.11.2858. · DOI
  152. R. Norman, J. Wang, W. H.-C. O. in Obstetrics, and undefined 2004, “Should we continue or stop insulin sensitizing drugs during pregnancy?,” journals.lww.com, Accessed: Aug. 21, 2022. [Online]. Available: https://journals.lww.com/co-obgyn/fulltext/2004/06000/should_we_continue_or_stop_insulin_sensitizing.7.aspx?casa_token=fkq-L3704Q0AAAAA:UXhl-h-gdaFui3IMGmuE0kZhlxWUVrnPCKD3-SxagZCdvFMLLPTSJJxh787DInABN-KLWi08qmiX_YaDqQHa7vHywaiQIQ
  153. Sreenan SK, et al. Calpains play a role in insulin secretion and action. Diabetes. 2001;50(9):2013–20. https://doi.org/10.2337/DIABETES.50.9.2013. · DOI
  154. Y. Horikawa et al., “Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus,” Nature Genetics 2000 26:2, vol. 26, no. 2, pp. 163–175, Oct. 2000, doi: https://doi.org/10.1038/79876. · DOI
  155. Gonzalez A, et al. CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(8):3971–6. https://doi.org/10.1210/JCEM.87.8.8793. · DOI
  156. Gonzalez A, et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab. 2003;88(11):5529–36. https://doi.org/10.1210/JC.2003-030322. · DOI
  157. H. F. Escobar-Morreale, B. Peral, G. Villuendas, R. M. Calvo, J. Sancho, and J. L. San Millán, “Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism,” Fertility and Sterility, vol. 77, no. 3, pp. 581–587, Mar. 2002, doi: https://doi.org/10.1016/S0015-0282(01)03206-X. · DOI
  158. Willer CJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet. 2009;41(1):25. https://doi.org/10.1038/NG.287. · DOI · Paper page
  159. Cai X, Liu C, Mou S. Association between fat mass- and obesity- associated (FTO) gene polymorphism and polycystic ovary syndrome: a meta-analysis. PLoS ONE. 2014;9(1):e86972. https://doi.org/10.1371/JOURNAL.PONE.0086972. · DOI
  160. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci. 2004;25(6):331–6. https://doi.org/10.1016/J.TIPS.2004.03.012. · DOI · Paper page
  161. Vidal-Puig AJ, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Investig. 1997;99(10):2416–22. https://doi.org/10.1172/JCI119424. · DOI · Paper page
  162. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(9):3299–306. https://doi.org/10.1210/JCEM.81.9.8784087. · DOI
  163. Azziz R, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–32. https://doi.org/10.1210/JCEM.86.4.7375. · DOI · Paper page
  164. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPARγ in humans. Mol Genet Metab. 2004;83(1–2):93–102. https://doi.org/10.1016/J.YMGME.2004.08.014. · DOI
  165. Urbanek M, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci. 1999;96(15):8573–8. https://doi.org/10.1073/PNAS.96.15.8573. · DOI
  166. Hahn S, et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol. 2005;62(5):573–9. https://doi.org/10.1111/J.1365-2265.2005.02261.X. · DOI
  167. Qu F, et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med. 2012;90(8):911–23. https://doi.org/10.1007/S00109-012-0881-4/FIGURES/5. · DOI
  168. Meczekalski B, Katulski K, Podfigurna-Stopa A, Czyzyk A, Genazzani AD. Spontaneous endogenous pulsatile release of kisspeptin is temporally coupled with luteinizing hormone in healthy women. Elsevier. 2016;105:1345-1350.e2. https://doi.org/10.1016/j.fertnstert.2016.01.029. · DOI
  169. Katulski K, Podfigurna A, Czyzyk A, Meczekalski B, Genazzani AD. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018;61(1):149–57. https://doi.org/10.1007/S12020-018-1609-1. · DOI
  170. E. A. Coutinho and A. S. Kauffman, “The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS),” Medical Sciences, 7, 8:84, 2019, https://doi.org/10.3390/MEDSCI7080084. · DOI
  171. Sullivan SD, Moenter SM. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci. 2004;101(18):7129–34. https://doi.org/10.1073/PNAS.0308058101. · DOI
  172. A. Moore, M. Prescott, R. C.- Endocrinology, and undefined 2013, “Estradiol negative and positive feedback in a prenatal androgen-induced mouse model of polycystic ovarian syndrome,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/endo/article-abstract/154/2/796/2423496 · DOI
  173. Moore AM, Prescott M, Marshall CJ, Yip SH, Campbell RE, McEwen BS. Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome. Proc Natl Acad Sci U S A. 2015;112(2):596–601. https://doi.org/10.1073/PNAS.1415038112/SUPPL_FILE/PNAS.201415038SI.PDF. · DOI
  174. S. Chhabra, C. McCartney, … R. Y.-T. J. of, and undefined 2005, “Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/90/5/2810/2836855 · DOI
  175. McCartney CR, Campbell RE, Marshall JC, Moenter SM. The role of gonadotropin-releasing hormone neurons in polycystic ovary syndrome. J Neuroendocrinol. 2022. https://doi.org/10.1111/JNE.13093). · DOI
  176. C. Eagleson, M. Gingrich, … C. P.-T. J. of, and undefined 2000, “Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and,” academic.oup.com, Accessed: Aug. 21, 2022. [Online]. Available: https://academic.oup.com/jcem/article-abstract/85/11/4047/2852619 · DOI · Paper page
  177. Dulka EA, Burger LL, Moenter SM. Ovarian androgens maintain high GnRH neuron firing rate in adult prenatally-androgenized female mice. Endocrinology. 2020;161(1):1–14. https://doi.org/10.1210/endocr/bqz038. · DOI
  178. M. Silva, M. Prescott, R. C.-J. insight, and undefined 2018, “Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS,” ncbi.nlm.nih.gov, Accessed: Aug. 21, 2022. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928858/ · DOI
  179. Wang C, Wen Y-X, Mai Q-Y. Impact of metabolic disorders on endometrial receptivity in patients with polycystic ovary syndrome. Exp Ther Med. 2022;23(3):221. https://doi.org/10.3892/ETM.2022.11145). · DOI
  180. G. F. Erickson and S. Shimasaki, “The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle,” Reproductive Biology and Endocrinology, 1, 2003, https://doi.org/10.1186/1477-7827-1-9 · DOI
  181. S. Shimasaki, R. Moore, … F. O.-E., and undefined 2004, “The bone morphogenetic protein system in mammalian reproduction,” academic.oup.com, Accessed: Aug. 22, 2022. [Online]. Available: https://academic.oup.com/edrv/article-abstract/25/1/72/2355266 · DOI · Paper page
  182. Elvin JA, Yan C, Matzuk MM. Oocyte-expressed TGF-β superfamily members in female fertility. Mol Cell Endocrinol. 2000;159(1–2):1–5. https://doi.org/10.1016/S0303-7207(99)00185-9. · DOI · Paper page
  183. Baarends WM, et al. Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinol. 1995;136(11):4951–62. https://doi.org/10.1210/ENDO.136.11.7588229. · DOI · Paper page
  184. von Schalburg KR, Mccarthy SP, Rise ML, Hutson JC, Davidson WS, Koop BF. Expression of morphogenic genes in mature ovarian and testicular tissues: potential stem-cell niche markers and patterning factors. Wiley Online Library. 2006;73(2):142–52. https://doi.org/10.1002/mrd.20359. · DOI
  185. A. Bourret et al., “BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis,” researchgate.net, 2012, https://doi.org/10.1530/EJE-12-0891. · DOI
  186. A. Fatehi, R. van den Hurk, B. C.- Theriogenology, and undefined 2005, “Expression of bone morphogenetic protein2 (BMP2), BMP4 and BMP receptors in the bovine ovary but absence of effects of BMP2 and BMP4 during IVM on bovine,” Elsevier, Accessed: Aug. 22, 2022. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0093691X04001645 · DOI
  187. J. Visser, F. de Jong, … J. L.-, and undefined 2006, “Anti-Mullerian hormone: a new marker for ovarian function,” rep.bioscientifica.com, Accessed: Aug. 22, 2022. [Online]. Available: https://rep.bioscientifica.com/view/journals/rep/131/1/1310001.xml · DOI · Paper page
  188. E. L. A. F. van Houten, J. S. E. Laven, Y. v. Louwers, A. McLuskey, A. P. N. Themmen, and J. A. Visser, “Bone morphogenetic proteins and the polycystic ovary syndrome,” Journal of Ovarian Research, 6, 1:1–4, 2013, https://doi.org/10.1186/1757-2215-6-32/TABLES/1. · DOI
  189. J. Zhang et al., “The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy,” Stem Cell Research and Therapy, vol. 6, no. 1, Dec. 2015, doi: https://doi.org/10.1186/S13287-015-0240-9. · DOI · Paper page
  190. M. Ullah, D. D. Liu, and A. S. Thakor, “Mesenchymal stromal cell homing: mechanisms and strategies for improvement,” iScience, 15:421–438, 2019, https://doi.org/10.1016/J.ISCI.2019.05.004. · DOI · Paper page
  191. Chapel A, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med. 2003;5(12):1028–38. https://doi.org/10.1002/JGM.452. · DOI
  192. A. J. Braga Osorio Gomes Salgado et al., “Adipose tissue derived stem cells secretome: soluble factors and their roles in regenerative medicine,” Current Stem Cell Research & Therapy, 5, 2:103–110, 2010, https://doi.org/10.2174/157488810791268564. · DOI · Paper page
  193. Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77(14):2771–94. https://doi.org/10.1007/S00018-020-03454-6. · DOI
  194. Q. Xie et al., “Mesenchymal stem cells alleviate DHEA-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice,” hindawi.com, Accessed: Aug. 22, 2022. [Online]. Available: https://www.hindawi.com/journals/sci/2019/9782373/ · DOI
  195. Z. KALHORI, M. AZADBAKHT, M. SOLEIMANI MEHRANJANI, and M. A. SHARIATZADEH, “Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome,” Cytotherapy, 20, 12:1445–1458, 2018, https://doi.org/10.1016/J.JCYT.2018.09.005 · DOI
  196. R. M. Chugh et al., “Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10,” Stem Cell Research and Therapy, 12, 1, 2021, https://doi.org/10.1186/S13287-021-02472-W. · DOI
  197. Marti N, Bouchoucha N, Sauter KS, Flück CE. Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities. PLoS ONE. 2017;12(3):e0174224. https://doi.org/10.1371/JOURNAL.PONE.0174224. · DOI
  198. P Kempná G Hofer P Mullis CF-M Pharmacology undefined, 2007 Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2 ASPET 2006https://doi.org/10.1124/mol.106.028902 · DOI
  199. I. Dilogo, J. Fiolin, P. A.-A. S. Letters, and undefined 2018, “Osteogenic potency of secretome bone marrow derived mesenchymal stem cells: a literature review,” ingentaconnect.com, Accessed: Aug. 22, 2022. [Online]. Available: https://www.ingentaconnect.com/contentone/asp/asl/2018/00000024/00000008/art00148
  200. Polacek M, Bruun J-A, Elvenes J, Figenschau Y, Martinez I. The secretory profiles of cultured human articular chondrocytes and mesenchymal stem cells: implications for autologous cell transplantation strategies. Cell Transplant. 2011;20:1381–93. https://doi.org/10.3727/096368910X550215. · DOI

200 of 241 shown

Cited by

Metadata

Authors
Siddiqui, S., Mateen, S., Ahmad, R., & Moin, S.
Venue
Journal of Assisted Reproduction and Genetics
Publisher
Springer Science and Business Media LLC
Published
2022-10-03
Volume
39
Issue
11
Pages
2439-2473
ISSN
  • 0740-7769 (ISSN-L)
  • 1058-0468
  • 1573-7330
DOI
10.1007/s10815-022-02625-7
OpenAlex
W4300089712
Cited by
347
References
37
FWCI
42.82
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.